Bioengineered Liver Support, Novel Therapeutics, and Predictive Modeling in Acute Liver Failure
Nov
2026
Description
This abstract session presents recent advances in the understanding and management of acute liver failure and acute-on-chronic liver failure. Topics include extracorporeal and bioengineered liver support devices, plasma exchange practices, novel molecular and cellular therapies, and the application of data-driven methods to guide treatment and predict outcomes.
Presentations
8:00 AM
- 8:15 AM
Convention Center - Mile High Ballroom 2A-3A
Human Liver Stem Cell-derived Exosomal miR-4492 Protects from Acute Liver Failure by Inhibiting IQGAP1-mediated Disulfidptosis
Qi Yang | Abstract Presenter
8:15 AM
- 8:30 AM
Convention Center - Mile High Ballroom 2A-3A
Does Continuous Renal Replacement Therapy Improve Survival in Acute Liver Failure and Acute-on-Chronic Liver Failure: A Time-Varying Analysis of 8,734 ICU Patients
Mohamed Nadeem, MD | Abstract Presenter
8:30 AM
- 8:45 AM
Convention Center - Mile High Ballroom 2A-3A
Development of a Volumetric 3D-Bioprinted Vascularized Artificial Liver for Transplantable Support in Liver Failure
Liwei Du | Abstract Presenter
8:45 AM
- 9:00 AM
Convention Center - Mile High Ballroom 2A-3A
Wide Practice Variation in Plasma Exchange for Acute Liver Failure Highlights Need for Evidence-Based Guidance
Paige E Hammis, MD | Abstract Presenter
9:00 AM
- 9:15 AM
Convention Center - Mile High Ballroom 2A-3A
ISRIB as a promising savior for acute liver failure: modulating the gut microbiota-tryptophan metabolism-immune axis
Qi Jiang | Abstract Presenter
9:15 AM
- 9:30 AM
Convention Center - Mile High Ballroom 2A-3A
Machine learning model accurately predicts spontaneous survival of phosphorus related hepatotoxicity patients treated with plasma exchange.
Ashish Goel, MD, DM, Ph.D | Abstract Presenter
